VIR - CIK 0001706431
Vir Biotechnology, Inc. (VIR) reported net income of -$437.99M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$437.99M | +16.1% |
| FY 2024 | -$521.96M | +15.1% |
| FY 2023 | -$615.12M | -219.2% |
| FY 2022 | $515.84M | -2.4% |
| FY 2021 | $528.58M | +277.0% |
| FY 2020 | -$298.67M | -71.0% |
| FY 2019 | -$174.68M | -50.7% |
| FY 2018 | -$115.88M | -65.9% |
| FY 2017 |
Vir Biotechnology, Inc. (VIR) reported net income of -$437.99M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Vir Biotechnology, Inc.'s net income declined from -$69.85M to -$437.99M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$69.85M |
| - |